Methylprednisolone sodium succinate combined with azithromycin in the treatment of Mycoplasma pneumonia in children and Its effect on immune function.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
OBJECTIVE: To investigate the clinical efficacy of methylprednisolone sodium succinate combined with azithromycin in the treatment of pediatric bronchopneumonia, and to explore its comprehensive effects on immune regulation and inflammation relief. METHODS: This retrospective controlled study included 120 pediatric patients with bronchopneumonia diagnosed in our hospital from October 2021 to March 2025. According to the treatment regimen, patients were divided into two groups: the experimental group (n = 60) received methylprednisolone sodium succinate combined with azithromycin on the basis of routine treatment, while the control group (n = 60) received azithromycin alone on the basis of routine treatment. The efficacy indicators before and after treatment, symptom improvement time (including time to defervescence, disappearance time of cough and sputum, resolution time of pulmonary rales, relief time of wheezing and dyspnea, time to disappearance of abnormal chest imaging, and length of hospital stay), inflammatory markers [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)] and immune parameters [immunoglobulin A (IgA), IgG, IgM] of the two groups were analyzed, and the adverse drug reactions during treatment were recorded. RESULTS: Compared with the control group, the overall efficacy of the experimental group was significantly better (total effective rate: 93.3% vs. 80.0%, P < 0.05). In terms of symptom improvement time, including time to fever resolution, disappearance of cough and sputum, resolution of pulmonary rales, relief of wheezing and dyspnea, disappearance of abnormal chest imaging and length of hospital stay, all indicators were significantly shortened in the experimental group (P < 0.05). After treatment, IL-6 and TNF-α levels were significantly decreased and IgA, IgG, and IgM levels were significantly increased in both groups, with more significant improvements observed in the experimental group (P < 0.05). The incidence of adverse drug reactions was similar between the two groups (8.3% vs. 13.3%, P > 0.05). CONCLUSION: Methylprednisolone sodium succinate combined with azithromycin can effectively shorten the course of mycoplasma bronchopneumonia in children, improve clinical symptoms, reduce inflammatory responses, and enhance immune responses. Under the premise of ensuring safety, it has advantages over azithromycin alone and has good clinical application prospects.